10 Best Life Sciences Stocks To Own Right Now

Small cap Biomed Realty Trust Inc (NYSE: BMR) is a real estate investment trust (REIT) offering an alternative way to gain exposure to the biotech or life sciences sector, meaning it might be worth taking a closer look at it along with a few benchmarks like the Vanguard REIT ETF (NYSEARCA: VNQ), iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI). Of course, it should be mentioned that REITs have had a rough ride lately�given all the ��apering��talk, but there is still a place for them in your portfolio with Biomed Realty Trust being one of the more unique offerings.

What is Biomed Realty Trust Inc?

Small cap Biomed Realty Trust is a fully integrated, self-administered and self-managed�REIT focused on providing real estate to the life science industry. Biomed Realty Trust has�over $5.0 billion invested in state-of-the-art research facilities and a world-class portfolio of life science buildings concentrated in the seven core�US life science markets of Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle.

Best Promising Companies To Invest In 2015: Oberbank AG (OBV)

Oberbank AG is an Austria-based commercial regional bank. The Company provides products and services for individual customers, as well as for corporate customers. It divides its operations into four segments: Corporate Customers, Private Customers, Financial Markets and Others. The Company offers credit and debit cards, current and saving accounts, investment services, electronic banking services, as well as financing, leasing, investment and real estate services. It operates through numerous offices in Austria, Germany, the Czech Republic, Hungary and Slovakia. The Company�� major shareholder is CABO Beteiligungsgesellschafts mbH with a stake of 32.54%. Advisors' Opinion:

• [By Tom Aspray]

  I have always felt it was important to give credit to those who originally developed or used a particular analytical tool. I still refer to the TRIN as the ARMs Index as it was developed by an old friend Dick Arms.  My favorite volume tool, of course, is the on-balance volume (OBV) and I frequently give credit to its creator, Joe Granville.

• [By Tom Aspray]

  In addition to the monthly, weekly, and daily charts I also look at the quarterly charts for a view of the longer-term trends. This chart of the S&P 500 and its on-balance volume (OBV) goes back to 1993. Since then, the quarterly OBV has crossed its 21-period WMA a total of five times.

• [By Tom Aspray]

  The daily on-balance volume (OBV) formed a bullish divergence, line c, at the lows. The bottom was confirmed by the move through the downtrend, line b, and the July high. The next level to watch is the 38.2% Fibonacci retracement resistance at $81.54 and then the 50% at $82.54. This decline in yields should be an opportunity to shorten the maturity of your bond holdings and reduce your exposure to the long end of the bond market.

• [By Tom Aspray]

  The high in August 2013 (point 2) just reached the 38.2% Fibonacci retracement resistance from the high at $174.07. This, therefore, was a key level of resistance. As prices declined from the highs, the daily on-balance volume (OBV) began a new downtrend and by October the OBV was acting weaker than prices.

10 Best Life Sciences Stocks To Own Right Now: ONYX Pharmaceuticals Inc.(ONXX)

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Nicholas Vardy]

  It's very much weighted toward some of the bigger stocks in the sector—Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), Celgene Corporation (CELG), Onyx (ONXX), which just received an unsolicited $10 billion bid, just in the past few weeks, and that would be really the best way to minimize your specific or company risk.

• [By Diane Alter]

  That's why Money Morning last week featured a number of moves investors can make to weather the uncertainty. In case you missed them, we've highlighted below the best investments and stocks to buy now given new and continuing market factors:

  The present bull market is looking old and tired at 54 months, a full 11 months longer than the average bull market run since 1953. Money Morning Chief Investment Strategist Keith Fitz-Gerald calls it the most unloved bull market in history. But there's no need to completely flee the market if you know the right moves to make. That's why we covered how to invest amid a market correction, plus how to invest in today's volatility. Money Morning Executive Editor William Patalon III rang up in-house energy expert Dr. Kent Moors to get the scoop on what investors need to do in the midst of mounting Middle East unrest. Moors, who runs our Energy Advantage advisory service, is one of best-connected insiders in the world's energy sector. He says investors should prepare themselves for the instability and continued surges in energy that will likely linger from a prolonged conflict. Speaking of moves to make right now, Money Morning's Global Investing & Income Strategist Robert Hsu warns investors to immediately find out how much exposure they have to real estate investment trusts (REITs), and in particular, mortgage REITs. You see, with mortgage rates spiking, REITs have come under pressure as worries grow that higher financing costs and rising capitalization rates (which often lead to lower property values) will weigh on the sector. A number of these investment vehicles are down some 24% to 30% in less than five months. Hsu cautions it is going to get a lot worse. That's why he's waving a red flag. Everyone needs to take note because practically every "properly divers

10 Best Life Sciences Stocks To Own Right Now: WestJet Airlines Ltd (WJA)

WestJet Airlines Ltd. (WestJet) provides airline service and travel packages with scheduled service to more than 85 destinations in North America, Central America and the Caribbean, and has partnership agreements with over 30 airlines around the world. WestJet operates a fleet of more than 100 Boeing Next-Generation 737 and Bombardier Q400 NextGen aircraft. The Company�� subsidiaries include WestJet Investment Corp., WestJet Operations Corp., WestJet Vacations Inc. and WestJet Encore Ltd. Advisors' Opinion:

• [By Eric Lam]

  BlackBerry, the smartphone maker looking to sell itself, lost 3.6 percent to pace declines among technology stocks. WestJet (WJA) Airlines Ltd. dropped 2.5 percent as load factor slipped in September. Valeant Pharmaceuticals International Inc. rose 1.4 percent after receiving approvals for products in the U.S. and Canada. Agrium Inc. added 0.7 percent after naming a successor for its retiring chief executive officer.

• [By Gerrit De Vynck]

  Closely held Porter unveiled plans in April to add as many as 30 CSeries jets in an order valued at as much as $2.1 billion from Montreal-based Bombardier to reach as far as Los Angeles and the Caribbean as it challenges the country�� two biggest carriers, Air Canada and WestJet Airlines Ltd. (WJA) The order, which would be Bombardier�� first for the aircraft with a Canadian carrier, is conditional on the runway extension and a removal of the jet ban.

10 Best Life Sciences Stocks To Own Right Now: Affymax Inc.(AFFY)

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.

Advisors' Opinion:

• [By Alpha Exposure]

  Investors in Affymax (AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the future for Omontys is in fact dire. At the conclusion of this article all doubt should be removed regarding the low likelihood that Omontys returns to market.

• [By Kanak Kanti De]

  Amgen needed an Onyx-like acquisition badly. For one, sales of Aranesp and Epogen, its flagship drugs for anemia, are dropping on concerns of safety, and loss of monopoly in 2012 to Affymax (AFFY), which received FDA approval for a rival anemia drug. (Note though, that after Omontys was recalled this year, that problem is resolved for Amgen.) Secondly, four of its top selling products go off patent in 2015.

10 Best Life Sciences Stocks To Own Right Now: Liberty Global Inc.(LBTYA)

Liberty Global, Inc. provides video, broadband Internet, and telephony services primarily in Europe and Chile. The company offers broadband services over cable distribution systems, including video, broadband Internet, and telephony; and video services through direct-to-home satellite, or through multichannel multipoint distribution systems. Its analog video services comprise basic and expanded basic programming; and digital cable services include basic and premium programming, digital video recorders, and high definition programming, as well as pay-per-view programming, such as video-on-demand and near video-on-demand. In addition, the company offers voice-over-Internet-protocol and circuit-switched telephony services, as well as mobile telephony services using third-party networks. Further, it owns programming networks that provide video programming channels to multi-channel distribution systems owned by the company and the third parties. As of December 31, 2011, the com pany owned and operated networks that passed 33,262,100 homes; and served 18,405,500 video subscribers, 8,159,300 broadband Internet subscribers, and 6,225,300 telephony subscribers. Liberty Global, Inc. was founded in 2004 and is based in Englewood, Colorado.

Advisors' Opinion:

• [By WWW.MARKETWATCH.COM]

  SAN FRANCISCO (MarketWatch) -- Philippe Laffont of Coatue Management gave Liberty Global's (LBTYA) stock a big boost on Monday after he noted how the company will benefit from increasing demand for broadband, in part due to Netflix's expansion. He also speculated the possiblity of a high-profile takeover from major mobile operators such as Vodafone (VOD) . Liberty Global is a cable holding company owned by John Malone. Shares of Liberty Global were up 2.2% and shares of Vodafone gained 0.6% following Laffont's presentation at the Ira Sohn conference .

• [By Sam Robson]

  LONDON -- Vodafone� (LSE: VOD  ) (NASDAQ: VOD  ) �is believed to have increased its offer for Kabel Deutschland following a rival bid from�Liberty Global� (NASDAQ: LBTYA  ) .

• [By Leo Fasciocco]

  The company, Liberty Global PLC (LBTYA), owns interests in broadband distribution and content companies in Europe, Asia, and Latin America, although the company is based in California.

• [By Monica Gerson]

  Breaking news

  Loews (NYSE: L) reported a 59% rise in its third-quarter earnings. Loews posted a quarterly profit of $282 million, or $0.73 per share, versus a year-ago profit of $177 million, or $0.45 per share. To read the full news, click here. BankUnited (NYSE: BKU) announced today the commencement of an underwritten offering of 9,000,000 shares of its common stock by certain of its existing stockholders, subject to market and other conditions. To read the full news, click here. Liberty Global (NASDAQ: LBTYA) announced today an agreement to sell substantially all of its international content division Chellomedia to AMC Networks (NASDAQ: AMCX).To read the full news, click here. Myriad Genetics (NASDAQ: MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted patients' risk of death from early-stage lung adenocarcinoma within five years of being diagnosed. To read the full news, click here.

  Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

10 Best Life Sciences Stocks To Own Right Now: Valhi Inc.(VHI)

Valhi, Inc., through its subsidiaries, operates in the chemicals, component products, and waste management businesses. Its Chemicals segment produces and markets titanium dioxide pigment, a white inorganic pigment used to impart whiteness, brightness, and opacity for applications, such as coatings, plastics and paper, inks, food, and cosmetics. It also mines ilmenite in Norway. The company?s Component Products segment manufactures mechanical and electrical cabinet locks and other locking mechanisms, including disc tumbler locks, pin tumbler locking mechanisms, and electronic locks for the postal, transportation, furniture, banking, vending, general cabinetry, and other industries. Its security products are used in various applications, including ignition systems, mailboxes, file cabinets, desk drawers, tool storage cabinets, vending and gaming machines, high security medical cabinetry, electrical circuit panels, storage compartments, gas station security, bank bags, and p arking meters. It also provides furniture components comprising precision ball bearing slides and ergonomic computer support systems for use in applications, such as file cabinets, desk drawers, computer related equipment, home appliances, tool storage cabinets, imaging equipment, and automated teller machines. In addition, this segment manufactures and distributes stainless steel exhaust components, gauges, throttle controls, hardware, and accessories primarily for performance boats. Valhi?s Waste Management segment engages in processing, treating, storing, and disposing hazardous, toxic, and low-level radioactive wastes. This segment serves chemical, aerospace, and electronics businesses, as well as governmental agencies. Valhi also offers insurance brokerage and risk management services; holds marketable securities; provides utility services; and owns and develops properties. The company was founded in 1932 and is based in Dallas, Texas. Valhi, Inc. is a subsidiary of Co ntran Corporation.

Advisors' Opinion:

• [By Ben Levisohn]

  Typically, when the chairman of a company dies, its shares drop. That hasn’t been the case for Valhi (VHI), Kronos Worldwide (KRO) and NL Industries (NL), which have all advanced today after Harold Simmons passed away.

10 Best Life Sciences Stocks To Own Right Now: UPM-Kymmene Corporation (UPM1V)

UPM-Kymmene Corporation is a Finland-based paper and forest products company. The Company operates, along with its subsidiaries, in three segments: the Energy and Pulp segment is divided into three units: Energy, which includes the Company�� hydropower plant and shares in energy companies; Pulp, which includes the Company�� pulp mills, and Foster and Timber, which includes forests, wood procurement, sawmills and further processing; the Paper segment includes the Company�� paper mills, producing magazine paper, newsprint, fine papers, and specialty papers, and the Engineered materials segment is structured into two units: Label, which includes label-stock factories and slitting, and distribution terminals, and Plywood, which includes plywood mills. The Company�� other operations include the wood plastic composite unit, development units and logistic services. On October 2, 2013, it completed the sale of the wood processing mill in Aigrefeuille d'Aunis, to Groupe FP Bois. Advisors' Opinion:

• [By Tom Stoukas]

  UPM-Kymmene (UPM1V), a rival maker of paper, dropped 1.9 percent to 10.23 euros.

  Aryzta surged 4 percent to 60.45 Swiss francs, the biggest gain since March 28. The owner of bakery brands including Delice de France and Otis Spunkmeyer posted full-year revenue of 4.5 billion euros ($6.1 billion), beating analysts��estimates of 4.43 billion euros. The company also forecast a double-digit percentage gain in 2014 earnings.

• [By Corinne Gretler]

  UPM-Kymmene Oyj (UPM1V) fell 3.9 percent to 12.18 euros. UBS AG lowered Europe�� second-largest papermaker to sell from neutral. The brokerage said that demand for the company�� product will not recover in Europe and that the industry will probably reduce its capacity next year.